Taking people in JapanNo phase
Special Drug Use-results Survey for Long-term Use (Fostamatinib)
Key facts
- Where
- Tokyo and Japanese Other Cities, JapanSee the site
Where in Japan
- Tokyo and Japanese Other CitiesHospital not named in the registryContact: Kazunori Abe, directorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Kissei Pharmaceutical Co., Ltd.
- Trial code
- NCT06757257
- Record updated
- 3 January 2025
- Original description
The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.Read full original descriptionShow less
The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.
Inclusion: Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.